Research programme: hormone therapy - Juniper Pharmaceuticals

Drug Profile

Research programme: hormone therapy - Juniper Pharmaceuticals

Alternative Names: Estrogen/progesterone intravaginal - Juniper Pharmaceuticals; JNP 0201; JNP 0301; Progesterone intravaginal - Juniper Pharmaceuticals

Latest Information Update: 18 Jan 2016

Price : $50

At a glance

  • Originator Juniper Pharmaceuticals
  • Class Gonadal steroid hormones; Hormonal replacements
  • Mechanism of Action Estrogen receptor modulators; Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Research Menopausal syndrome; Preterm labour

Most Recent Events

  • 11 Jan 2016 Juniper intends to submit an IND to the US FDA for JNP-0201 in 2017
  • 13 Nov 2015 Early research in Menopausal syndrome in USA (Vaginal)
  • 13 Nov 2015 Early research in Preterm labour in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top